Genetic Technologies Limited

For the year ended June 30, 2023, Genetic Technologies reported cash receipts of A$8.8 million, up 29% year over year, gross margin of A$4.2 million, or 47%, and cash at bank of A$7.9 million. In the quarter, cash receipts were A$2.1 million, and geneType commercial samples increased 250% versus the prior quarter. Management said the company believes a pathway to profitability could be achieved by the middle of financial year 2025. No formal next-quarter revenue or EPS guidance was provided; instead, the company pointed to upcoming milestones including the launch of the UNITY prenatal test, a hereditary breast and ovarian cancer test, and a pilot with a payer or medical institution.

Simon Morriss emphasized that the business is moving from a long R&D phase into commercialization and then toward profitability, with revenue growth as the central priority. He repeatedly framed the strategy around three brands — geneType, EasyDNA, and Affinity DNA — plus a multi-channel model spanning B2B payers/distributors, consumer-initiated testing, and direct-to-consumer. His tone was optimistic and milestone-driven, highlighting U.S. commercial progress, upcoming clinical validation work, and new product launches as the key next steps.

Tony Di Pietro focused on integration and control after the acquisitions, saying the two businesses bought in the last two years broadened exposure to direct-to-consumer markets and European operations. He said systems and reporting lines have now been embedded, with efficiency gains now the focus, and noted the challenge of managing a globally distributed business from Melbourne across multiple time zones. On risk management, he said cybersecurity has long been a priority because of patient data, and that the new businesses have moved to Office 365 while Melbourne is undergoing a similar upgrade.

Analysts asked about the main growth drivers, and management said the core levers are sales from the existing EasyDNA and Affinity businesses, growth in geneType, and especially securing a U.S. payer or distributor relationship. On ESG, management rejected the idea that it is box ticking, saying investors care about it and the company has completed a baseline report and is now setting milestones. On U.S. payer talks, Carl Stubbings said the team is close to finalizing the foundation for reimbursement discussions and that a pilot should help move other payer conversations forward.